Hepatocellular carcinoma in Navarre: study of characteristics and evolution in clinical practice
DOI:
https://doi.org/10.23938/ASSN.0269Keywords:
Hepatocellular carcinoma. Epidemiology. Screening.Abstract
Background. Hepatocellular carcinoma generally arises in a cirrhotic liver. The aim of screening is to improve survival. The aims of our study are to determine the characteristics and evolution of hepatocellular carcinoma and the effect of screening on survival, in clinical practice in Navarre.
Methods. Prospective and retrospective study of 111 patients diagnosed with hepatocellular carcinoma in public hospitals in Navarre between January 2009 and January 2015. Epidemiological, clinical, analytical, radiological characteristics, tumour staging, treatment and evolution were analyzed. Survival was compared between patients subjected to screening and those not.
Results. Mean age was 67 years. The patients (84.7%) were mainly male and 85.6% had cirrhosis. The most frequent aetiology was alcohol consumption (40.7%). 62.2% were diagnosed in early stages, 15.3% in intermediate and 22.5 % in advanced or terminal stages. 4.5% received transplants, 21.6% received surgical resection, 23.4% were treated with ablation techniques, 10.8 % with chemoembolization, 5.4% with radiembolization, 2.7% with embolization, 13.5 % with sorafenib and 18% symptomatically. Only 32 patients (28.8%) were subjected to screening. No statistical differences were found in survival depending on surveillance (32 month versus 34; p = 0.971).
Conclusions. In Navarre, hepatocellular carcinoma generally appears against a background of cirrhosis, and alcohol is the most frequent aetiology. Hepatocellular carcinoma is diagnosed most frequently in early stages and out of screening practices. Screening was not associated to better survival.
Downloads
References
1. FERLAY J, SOERJOMATARAM I, DIKSHIT R, ESER S, MATHERS C, REBELO M et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-E386.
https://doi.org/10.1002/ijc.29210
2. GOMAA AI, KHAN SA, TOLEDANO MB, WAKED I, TAYLOR-ROBINSON SD. Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008; 14: 4300-4308.
https://doi.org/10.3748/wjg.14.4300
3. BOSCH FX, RIBES J, DIAZ M, XLERIES R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127 (5 Suppl 1): S5-S16.
https://doi.org/10.1053/j.gastro.2004.09.011
4. ALTEKRUSE SF, MCGLYNN, KA, REICHMAN ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-1491.
https://doi.org/10.1200/JCO.2008.20.7753
5. ZHANG Y, REN JS, SHI JF, LI N, WANG YT, QU C et al. International trends in primary liver cancer incidence from 1973 to 2007. BMC Cancer 2015; 15: 94.
https://doi.org/10.1186/s12885-015-1113-4
6. CENTER MM, JEMAL A. International trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2011; 20: 2362-2368.
https://doi.org/10.1158/1055-9965.EPI-11-0643
7. CAPOCACCIA R, SANT M, BERRINO F, SIMONETTI A, SANTI V, TREVISANI F et al. Hepatocellular carcinoma: trends of incidence and survival at the end of the 20th Century. Am J Gastroenterol 2007; 102: 1661-1670.
https://doi.org/10.1111/j.1572-0241.2007.01337.x
8. BEASLEY RP, HWANG KY, LIN CC, CHIEN CS. Lancet 1981; 21: 1129- 1133
https://doi.org/10.1016/S0140-6736(81)90585-7
9. VARELA M, REIG M, DE LA MATA M, MATILLA A, BUSTAMANTE J et al. Tratamiento del carcinoma hepatocelular en España. Análisis de 705 casos en 62 centros. Med Clin 2010; 134: 569-576.
https://doi.org/10.1016/j.medcli.2009.10.042
10. GÓMEZ RODRÍGUEZ R, ROMERO GUTIÉRREZ M, GONZÁLEZ DE FRUTO C, DE ARTAZA VARASA T, DE LA CRUZ PEREZ G, CIAMPI DOPAZO J et al. Características clínicas, estatificación y tratamiento de los pacientes con carcinoma hepatocelular en la práctica clínica. Estudio prospectivo de una serie de 136 pacientes. Gastroenterol Hepatol 2011; 34: 524-531.
https://doi.org/10.1016/j.gastrohep.2011.06.009
11. VERGARA M, GIL M, DALMAU B, RIBOT R, NAVARRO C, MARTIN A et al. Natural history of hepatocellular carcinoma in a cohort of patients from a county hospital. Rev Esp Enferm Dig. 2008; 100: 682-687.
https://doi.org/10.4321/S1130-01082008001100003
12. FORMAN D, BRAY F, BREWSTER DH, GOMBE MBALAWA C, KOHLER B, PIÑEROS M et al. Cancer Incidence in Five Continents, Vol. X (http://ci5.iarc.fr/CI5-X/Pages/bySite3_sel.aspx).
13. BRUIX J, SHERMAN M. AASLD practice guideline. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
https://doi.org/10.1002/hep.24199
14. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
https://doi.org/10.1016/j.jhep.2011.12.001
15. FORNER A, REIG M, VARELA M, BURREL M, FELIU J, BRICEÑO J et al. Diagnóstico y tratamiento del carcinoma hepatocelular. Actualización del documento de consenso de la AEEH, SEOM, SERAM, SERVEI y SETH. Med Clin (Barc). 2016; http://dx.doi.org/10.1016/j.medcli.2016.01.028
https://doi.org/10.1016/j.medcli.2016.01.028
16. LLOVET JM, BRÚ C, BRUIX J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
https://doi.org/10.1055/s-2007-1007122
17. YOPP AC, CHOTI MA. Non-alcoholic steatohepatitis-related hepatocellular carcinoma: a growing epidemic? Dig Dis 2015; 33: 642-647.
https://doi.org/10.1159/000438473
18. JINJUVADIA R, PATEL S, LIANGPUNSAKUL S. The Association between metabolic syndrome and hepatocellular carcinoma: Systematic review and meta-analysis. J Clin Gastroenterol 2014; 48: doi:10.1097/MCG.0b013e3182a030c4
https://doi.org/10.1097/MCG.0b013e3182a030c4
19. BOLONDI L, SOFIA S, SIRINGO S, GAIANI S, CASALI A, ZIRONI G et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001; 48: 251-259.
https://doi.org/10.1136/gut.48.2.251
20. SARKAR M, STEWART S, YU A, CHEN MS, NGUYEN TT, KHALILL M. J. Hepatocellular carcinoma screening practices and impact on survival among hepatitis B-infected Asian Americans. Viral Hepatol 2002; 19: 594-600.
https://doi.org/10.1111/j.1365-2893.2011.01577.x
21. COLOMBO M, DE FRANCHIS R, DEL NINNO E, SANGIOVANNI A, DE FAZIO C, TOMMASINI M et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 675-680.
https://doi.org/10.1056/NEJM199109053251002
22. PATERON D, GANNE N, TRINCHET JC, AUROUSSEAU MH, MAL F, MEICLER C et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994; 20: 65-71.
https://doi.org/10.1016/S0168-8278(05)80468-4
23. CHEN JD, PARKIN DM, CHEN QG, LU JH; SHEN QJ, ZHANG BC et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen 2003; 10: 204-209.
https://doi.org/10.1258/096914103771773320
24. ZHANG BH, YANG BH, TANG ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-422.
https://doi.org/10.1007/s00432-004-0552-0
25. YANG B, ZHANG B, XU Y, WANG W, SHEN Y, ZHANG A et al. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol 1997; 123: 357-360.
https://doi.org/10.1007/BF01438313
26. SINGAL A, VOLK ML, WALJEE A, SALGIA R, HIGGINS P, ROGERS AM et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30: 37-47.
Published
How to Cite
Issue
Section
License
Copyright (c) 2016 Anales del Sistema Sanitario de Navarra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
